Helium is an inert gas with a density almost one-seventh of that of air. Based on its properties breathing a mixture of helium and oxygen (heliox) will lead to a reduction in resistance through narrowed airways and consequently decreases the work of breathing. Participating infants with RSV acute bronchiolitis will be supplied with heliox (ration of 21 oxygen and 79 helium) delivered through a flow nasal cannula to evaluate heliox effect in improving their oxygenation. Heliox will act as an additive therapy to improve oxygenation in patients with lower respiratory tract infection caused by respiratory Syncytial Virus (RSV) and will decrease the need for more complicated therapies.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
104
Heliox (21:79) via nasal cannula 2 litter per minutes
Air 21% via nasal cannula 2 litter per minutes
Improvement in oxygenation
Arterial blood samples will be withdrawn through an arterial stab to determine partial pressure of arterial oxygen (PaO2)
Time frame: change from baseline at 24 hours after treatment
improvement of respiratory distress
measured by the Modified Wood's Clinical Asthma Score
Time frame: change from baseline at 24 hours after treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.